deltatrials
Recruiting PHASE1 INTERVENTIONAL 1-arm NCT03454035

Ulixertinib/Palbociclib in Patients With Advanced Pancreatic and Other Solid Tumors

Ulixertinib (BVD-523) in Combination With Palbociclib in Patients With Advanced Solid Tumors With Expansion Cohort in Previously Treated Metastatic Pancreatic Cancer and Metastatic RAS-mutant and NF1-mutant (no BRAFV600 Mutations) Melanoma

Sponsor: BioMed Valley Discoveries, Inc

Conditions Melanoma Pancreatic Cancer Tumor, Solid
Interventions Palbociclib Ulixertinib
Updated 18 times since 2018 Last updated: Sep 10, 2025 Started: Jan 30, 2018 Primary completion: Jul 15, 2026 Completion: Nov 24, 2026
This information is for research purposes only and is not medical advice. Consult a healthcare provider before making any medical decision.

This PHASE1 trial investigates Melanoma and Pancreatic Cancer and is currently actively recruiting participants. BioMed Valley Discoveries, Inc leads this study, which shows 18 recorded versions since 2018 — indicating substantial longitudinal coverage. As an oncology study, it adds to the longitudinal record of treatment development for this indication.

Status Flow

~Mar 2018 – ~Apr 2018 · 31 days · monthly snapshot~Apr 2018 – ~Jun 2018 · 2 months · monthly snapshot~Jun 2018 – ~Jan 2019 · 7 months · monthly snapshot~Jan 2019 – ~Feb 2020 · 13 months · monthly snapshot~Feb 2020 – ~Jan 2021 · 11 months · monthly snapshot~Jan 2021 – ~May 2021 · 4 months · monthly snapshot~May 2021 – ~Feb 2022 · 9 months · monthly snapshot~Feb 2022 – ~Sep 2022 · 7 months · monthly snapshot~Sep 2022 – ~Nov 2022 · 2 months · monthly snapshot~Nov 2022 – ~Dec 2022 · 30 days · monthly snapshot~Dec 2022 – ~Jan 2023 · 31 days · monthly snapshot~Jan 2023 – ~May 2023 · 4 months · monthly snapshot~May 2023 – ~Feb 2024 · 9 months · monthly snapshot~Feb 2024 – ~Jul 2024 · 5 months · monthly snapshot~Jul 2024 – ~Sep 2024 · 2 months · monthly snapshot~Sep 2024 – ~Apr 2025 · 7 months · monthly snapshot~Apr 2025 – ~Oct 2025 · 6 months · monthly snapshot~Oct 2025 – present · 9 months · monthly snapshot

Change History

18 versions recorded

  1. Oct 2025 — Present [monthly]

    Recruiting PHASE1

  2. Apr 2025 — Oct 2025 [monthly]

    Recruiting PHASE1

  3. Sep 2024 — Apr 2025 [monthly]

    Recruiting PHASE1

  4. Jul 2024 — Sep 2024 [monthly]

    Recruiting PHASE1

  5. Feb 2024 — Jul 2024 [monthly]

    Recruiting PHASE1

▶ Show 13 earlier versions

  1. May 2023 — Feb 2024 [monthly]

    Recruiting PHASE1

  2. Jan 2023 — May 2023 [monthly]

    Recruiting PHASE1

  3. Dec 2022 — Jan 2023 [monthly]

    Recruiting PHASE1

    Status: Active Not Recruiting → Recruiting

  4. Nov 2022 — Dec 2022 [monthly]

    Active Not Recruiting PHASE1

  5. Sep 2022 — Nov 2022 [monthly]

    Active Not Recruiting PHASE1

  6. Feb 2022 — Sep 2022 [monthly]

    Active Not Recruiting PHASE1

    Status: Recruiting → Active Not Recruiting

  7. May 2021 — Feb 2022 [monthly]

    Recruiting PHASE1

  8. Jan 2021 — May 2021 [monthly]

    Recruiting PHASE1

  9. Feb 2020 — Jan 2021 [monthly]

    Recruiting PHASE1

  10. Jan 2019 — Feb 2020 [monthly]

    Recruiting PHASE1

  11. Jun 2018 — Jan 2019 [monthly]

    Recruiting PHASE1

  12. Apr 2018 — Jun 2018 [monthly]

    Recruiting PHASE1

  13. Mar 2018 — Apr 2018 [monthly]

    Recruiting PHASE1

    First recorded

Jan 2018

Trial started

Per CT.gov start date — pre-dates our first snapshot

Eligibility Summary

No eligibility information available.

Contact Information

Sponsor contact:
  • BioMed Valley Discoveries, Inc
  • Pfizer
  • UNC Lineberger Comprehensive Cancer Center
Data source: UNC Lineberger Comprehensive Cancer Center

For direct contact, visit the study record on ClinicalTrials.gov .

Study Locations